ADPT
Adaptive Biotechnologies Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+47/100
Last price
26.90
▼ 2.94 (9.85%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
29.84
Day high
30.74
Day low
26.85
Volume
2.53M
Market cap
$4.29B
P/E (TTM)
—
52W range
12.00 – 30.74
Trailing performance
Returnvs SPY
1W
-6.50%
-8.4%
1M
+10.79%
+9.6%
3M
+33.43%
+28.9%
6M
+96.21%
+78.0%
YTD
+65.64%
+51.4%
1Y
+87.07%
+70.6%
3Y
+393.58%
+311.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ADPT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-1.17M
Net selling
Buy transactions
19
1.62M shares
Sell transactions
32
2.79M shares
Net transactions
+51
Buys less sells
Sell : buy shares
1.7 : 1
Mixed
Insider-held shares
2.06M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 5, 26 | RUBINSTEIN JULIAN President |
CONVERSION | 35.64K | $432.71K | Direct |
| Oct 5, 26 | RUBINSTEIN JULIAN President |
SELL | 35.64K | $1.01M | Direct |
| Oct 1, 26 | LO FRANCIS Officer |
CONVERSION | 26.79K | $181.56K | Direct |
| Oct 1, 26 | LO FRANCIS Officer |
SELL | 26.79K | $757.70K | Direct |
| Sep 15, 26 | BOBULSKY SUSAN Officer |
SELL | 1.20K | $32.27K | Direct |
| Aug 31, 26 | OWEN KATEY EINTERZ Director |
STOCK | 12.54K | $0 | Direct |
| Aug 26, 26 | OWEN KATEY EINTERZ Director |
SELL | 9.62K | $249.99K | Direct |
| Aug 18, 26 | ROBINS CHAD M Chief Executive Officer |
CONVERSION | 600.00K | $3.93M | Direct |
| Aug 18, 26 | HERSHBERG ROBERT M Director |
CONVERSION | 15.00K | $94.80K | Direct |
| Aug 18, 26 | HERSHBERG ROBERT M Director |
SELL | 30.66K | $748.21K | Direct |
| Aug 18, 26 | ROBINS CHAD M Chief Executive Officer |
SELL | 600.00K | $14.88M | Direct |
| Aug 17, 26 | NEUPERT PETER M Director |
CONVERSION | 15.00K | $94.80K | Direct |
| Aug 17, 26 | NEUPERT PETER M Director |
SELL | 124.69K | $3.14M | Direct |
| Aug 10, 26 | BOBULSKY SUSAN Officer |
SELL | 3.00K | $75.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BENZENO SHARON |
Officer | 221.28K | Conversion of Exercise of derivative security |
BOBULSKY SUSAN |
Officer | 395.79K | Sale |
LO FRANCIS |
Officer | 223.37K | Conversion of Exercise of derivative security |
NEUPERT PETER M |
Director | 130.63K | Conversion of Exercise of derivative security |
OWEN KATEY EINTERZ |
Director | 66.10K | Stock Gift |
PELLINI MICHAEL J |
Director | 69.69K | Stock Award(Grant) |
PISKEL KYLE |
Chief Financial Officer | 256.73K | Sale |
ROBINS CHAD M |
Chief Executive Officer | 2.18M | Conversion of Exercise of derivative security |
ROBINS HARLAN S. |
Officer | 812.06K | Conversion of Exercise of derivative security |
RUBINSTEIN JULIAN |
President | 377.80K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$4.29B
Enterprise value$4.37B
Revenue (TTM)$308.08M
Gross profit$144.62M
EBITDA$-21.33M
Net income$-63.85M
EPS (TTM)$-0.41
Free cash flow$18.98M
Total cash$344.26M
Total debt$410.50M
Book value / share$0.90
Shares outstanding159.60M
Float125.48M
Short % of float10.68%
Dividend yield0.00%
Beta (5Y)2.10
Valuation & profitability ratios
Trailing P/E—
Forward P/E-149.07
PEG ratio—
Price / sales—
Price / book29.96
EV / revenue14.18
EV / EBITDA-204.77
Gross margin46.94%
Operating margin-22.04%
Profit margin-20.73%
Return on equity-38.76%
Return on assets-4.12%
Debt / equity272.46
Current ratio4.80
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $276.98M | $178.96M | $170.28M | $185.31M | +54.8% |
| Operating revenue | $276.98M | $178.96M | $170.28M | $185.31M | +54.8% |
| Cost of revenue | $71.36M | $72.08M | $75.55M | $57.91M | -1.0% |
| Gross profit | $205.62M | $106.88M | $94.72M | $127.40M | +92.4% |
| Research & development | $93.77M | $102.95M | $122.12M | $141.76M | -8.9% |
| Selling, general & admin | $167.27M | $157.56M | $172.51M | $184.13M | +6.2% |
| Total operating expense | $262.74M | $262.22M | $296.33M | $327.58M | +0.2% |
| Operating income | -$57.12M | -$155.34M | -$201.61M | -$200.19M | +63.2% |
| Net interest income | -$2.33M | $2.95M | $1.73M | -$182.00K | -179.0% |
| Pre-tax income | -$59.46M | -$159.59M | -$225.30M | -$200.37M | +62.7% |
| Net income | -$59.50M | -$159.49M | -$225.25M | -$200.19M | +62.7% |
| Net income to common | -$59.50M | -$159.49M | -$225.25M | -$200.19M | +62.7% |
| Basic EPS | -0.39 | -1.08 | -1.56 | -1.40 | +63.9% |
| Diluted EPS | -0.39 | -1.08 | -1.56 | -1.40 | +63.9% |
| EBIT | -$47.68M | -$148.01M | -$211.50M | -$196.13M | +67.8% |
| EBITDA | -$29.85M | -$128.76M | -$189.27M | -$175.21M | +76.8% |
| Basic shares | 151.72M | 147.10M | 144.38M | 142.52M | +3.1% |
| Diluted shares | 151.72M | 147.10M | 144.38M | 142.52M | +3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $70.50M | $47.92M | $65.06M | $90.03M | +47.1% |
| Cash & short-term investments | $226.98M | $222.29M | $346.40M | $498.20M | +2.1% |
| Accounts receivable | $50.37M | $41.73M | $37.97M | $40.06M | +20.7% |
| Inventory | $9.82M | $8.44M | $14.45M | $14.45M | +16.4% |
| Total current assets | $300.19M | $283.75M | $410.19M | $562.15M | +5.8% |
| Property, plant & equipment | $74.72M | $94.38M | $120.32M | $164.21M | -20.8% |
| Goodwill & intangibles | $120.70M | $122.40M | $124.10M | $125.80M | -1.4% |
| Total assets | $512.74M | $539.38M | $661.13M | $856.62M | -4.9% |
| Total current liabilities | $89.92M | $98.05M | $88.02M | $109.79M | -8.3% |
| Total debt | $79.15M | $89.39M | $98.77M | $108.00M | -11.5% |
| Total liabilities | $287.74M | $336.89M | $352.86M | $392.52M | -14.6% |
| Retained earnings | -$1.36B | -$1.30B | -$1.14B | -$919.08M | -4.6% |
| Shareholder equity | $218.79M | $202.71M | $308.40M | $464.17M | +7.9% |
| Working capital | $210.27M | $185.70M | $322.17M | $452.36M | +13.2% |
| Net tangible assets | $98.09M | $80.31M | $184.30M | $338.37M | +22.1% |
| Shares issued | 153.78M | 147.77M | 145.08M | 143.11M | +4.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$59.46M | -$159.59M | -$225.30M | -$200.37M | +62.7% |
| Depreciation & amortisation | $17.83M | $19.26M | $22.23M | $20.92M | -7.4% |
| Stock-based compensation | $51.48M | $53.61M | $62.91M | $55.48M | -4.0% |
| Change in working capital | -$57.77M | -$17.45M | -$46.18M | -$71.55M | -231.0% |
| Operating cash flow | -$45.99M | -$95.21M | -$156.32M | -$183.94M | +51.7% |
| Capital expenditure | -$2.96M | -$3.66M | -$10.70M | -$16.35M | +19.2% |
| Investing cash flow | $37.95M | $77.79M | $129.65M | $2.90M | -51.2% |
| Financing cash flow | $30.40M | $241.00K | $2.25M | $132.26M | +12,515.4% |
| Free cash flow | -$48.95M | -$98.88M | -$167.02M | -$200.29M | +50.5% |
| End cash position | $73.18M | $50.82M | $68.00M | $92.43M | +44.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $71.55M | $70.87M | $71.68M | $93.97M | $58.88M | +1.0% |
| Operating revenue | $71.55M | $70.87M | $71.68M | $93.97M | $58.88M | +1.0% |
| Cost of revenue | $20.16M | $18.71M | $18.22M | $18.16M | $18.00M | +7.8% |
| Gross profit | $51.39M | $52.17M | $53.46M | $75.82M | $40.88M | -1.5% |
| Research & development | $19.15M | $23.62M | $21.76M | $23.67M | $24.13M | -18.9% |
| Selling, general & admin | $47.58M | $47.33M | $44.04M | $41.43M | $41.36M | +0.5% |
| Total operating expense | $67.16M | $71.37M | $66.23M | $65.53M | $65.92M | -5.9% |
| Operating income | -$15.77M | -$19.21M | -$12.77M | $10.29M | -$25.04M | +17.9% |
| Net interest income | -$438.00K | -$809.00K | -$806.00K | -$745.00K | -$557.00K | +45.9% |
| Pre-tax income | -$39.94M | -$20.02M | -$13.58M | $9.54M | -$25.59M | -99.6% |
| Net income | -$39.79M | -$20.03M | -$13.58M | $9.55M | -$25.61M | -98.6% |
| Net income to common | -$39.79M | -$20.03M | -$13.58M | $9.55M | -$25.61M | -98.6% |
| Basic EPS | -0.25 | -0.13 | -0.09 | 0.06 | -0.17 | -92.3% |
| Diluted EPS | -0.25 | -0.13 | -0.09 | 0.06 | -0.17 | -92.3% |
| EBIT | -$37.25M | -$17.13M | -$10.63M | $12.52M | -$22.64M | -117.5% |
| EBITDA | -$33.55M | -$13.29M | -$6.43M | $16.92M | -$18.14M | -152.5% |
| Basic shares | 159.86M | 155.52M | 153.13M | 152.43M | 152.08M | +2.8% |
| Diluted shares | 159.86M | 155.52M | 153.13M | 163.16M | 152.08M | +2.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $169.87M | $77.58M | $70.50M | $55.03M | $43.16M | +119.0% |
| Cash & short-term investments | $344.25M | $218.33M | $226.98M | $212.77M | $197.87M | +57.7% |
| Accounts receivable | $49.51M | $48.31M | $50.37M | $44.82M | $44.28M | +2.5% |
| Inventory | $10.50M | $11.21M | $9.82M | $9.93M | $8.40M | -6.3% |
| Total current assets | $420.56M | $291.81M | $300.19M | $281.44M | $261.86M | +44.1% |
| Property, plant & equipment | $68.57M | $71.02M | $74.72M | $79.49M | $84.39M | -3.4% |
| Goodwill & intangibles | $119.86M | $120.28M | $120.70M | $121.13M | $121.56M | -0.4% |
| Total assets | $640.68M | $505.94M | $512.74M | $490.61M | $496.64M | +26.6% |
| Total current liabilities | $87.71M | $87.01M | $89.92M | $83.36M | $92.14M | +0.8% |
| Long-term debt | $334.88M | — | — | — | — | — |
| Total debt | $410.50M | $77.63M | $79.15M | $81.80M | $84.37M | +428.8% |
| Total liabilities | $490.02M | $281.70M | $287.74M | $286.36M | $317.10M | +73.9% |
| Retained earnings | -$1.42B | -$1.38B | -$1.36B | -$1.35B | -$1.36B | -2.9% |
| Shareholder equity | $142.91M | $216.34M | $218.79M | $204.44M | $179.72M | -33.9% |
| Working capital | $332.85M | $204.80M | $210.27M | $198.07M | $169.72M | +62.5% |
| Net tangible assets | $23.06M | $96.06M | $98.09M | $83.31M | $58.16M | -76.0% |
| Shares issued | 159.06M | 159.70M | 153.78M | 152.58M | 152.23M | -0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$39.94M | -$20.02M | -$13.58M | $9.54M | -$25.59M | -99.6% |
| Depreciation & amortisation | $3.69M | $3.84M | $4.20M | $4.41M | $4.50M | -3.7% |
| Stock-based compensation | $11.12M | $11.93M | $12.72M | $13.26M | $13.36M | -6.8% |
| Change in working capital | $222.00K | -$6.29M | -$2.45M | -$33.87M | -$5.30M | +103.5% |
| Operating cash flow | -$6.40M | -$9.54M | $2.06M | -$7.13M | -$12.43M | +32.9% |
| Capital expenditure | -$1.18M | -$796.00K | -$636.00K | -$409.00K | -$655.00K | -48.7% |
| Investing cash flow | -$43.48M | $9.14M | -$8.25M | $17.28M | $3.35M | -575.5% |
| Financing cash flow | $142.19M | $7.50M | $21.66M | $1.68M | $1.61M | +1,795.8% |
| Free cash flow | -$7.58M | -$10.33M | $1.42M | -$7.54M | -$13.09M | +26.6% |
| End cash position | $172.60M | $80.29M | $73.18M | $57.72M | $45.88M | +115.0% |
Options analytics
Put / call volume
1.75
Put-heavy session
Put / call open interest
0.50
Positioning, not flow
Max pain
5.00
-81.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
36
Contracts, this expiry
Put volume
63
Contracts, this expiry
Heaviest call OI
12.50
2 contracts
Heaviest put OI
5.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.13 | -0.25 | -87.2% |
| Mar 2026 | -0.16 | -0.13 | +20.2% |
| Dec 2025 | -0.18 | -0.09 | +50.8% |
| Sep 2025 | -0.14 | 0.06 | +143.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.10 | 7 | $71.64M | -23.8% |
| Next quarter | -0.06 | 7 | $79.24M | +10.6% |
| Current year | -0.54 | 7 | $293.43M | +5.9% |
| Next year | -0.18 | 7 | $359.22M | +22.4% |
Analyst targets & ownership
Mean target$28.31
High target$35.00
Low target$21.00
Implied upside5.25%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy2 / 6
Hold1
Sell / Strong sell0 / 0
Held by insiders1.29%
Held by institutions99.50%
Institutions holding423
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
28.55
-5.79% from price
SMA 20
27.53
-2.29% from price
SMA 50
25.83
+4.15% from price
SMA 100
22.12
+21.62% from price
SMA 200
18.78
+43.22% from price
EMA 12
28.10
-4.26% from price
EMA 26
27.23
-1.20% from price
EMA 50
25.71
+4.63% from price
RSI (14)
48.8
Neutral
MACD (12,26,9)
0.87
Hist -0.14
ATR (14)
1.46
5.44% of price
Realised vol 30D
54.6%
Annualised
Bollinger upper
31.03
20, 2σ
Bollinger lower
24.03
20, 2σ
50 / 200 cross
Golden
25.83 vs 18.78
Trend bias
Above 200
+43.22%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.64
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
54.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.3%
Peak to trough
Max drawdown 5Y
-93.7%
Peak to trough
ATR 14
1.46
5.44% of price
Beta (reported)
2.10
5Y monthly, from filing
Short interest
Shares short
13.49M
Prior 13.32M
Change vs prior
+1.2%
Shorts adding
% of float
10.68%
Elevated
% of shares out
8.45%
Against total outstanding
Days to cover
7.5
Crowded exit
Float
125.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 29, 26 | Goldman Sachs | INITIATED | — | Buy |
| Sep 22, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 4, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 30, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 30, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 30, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 9, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jun 29, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 17, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 12, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K · 2026-06-09
Periodic Financial Reports
10-Q · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-24
Offering Registrations
S-8 · 2026-02-27
Headlines
Adaptive Biotechnologies Insider Sold Shares Worth $1,014,329, According to a Recent SEC Filing
MT Newswires · 1d ago
Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update
Simply Wall St. · 11d ago
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
GlobeNewswire · 12d ago
Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?
Simply Wall St. · 12d ago
NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)
Simply Wall St. · 13d ago
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
Insider Monkey · 14d ago
Adaptive Biotechnologies Insider Sold Shares Worth $3,238,004, According to a Recent SEC Filing
MT Newswires · 16d ago
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
GlobeNewswire · 20d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.